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Patients with type 2 diabetes (T2D) often exhibit hyperglucago-
nemia despite hyperglycemia, implicating defective a-cell func-
tion. Although endoplasmic reticulum (ER) stress has been
suggested to underlie b-cell dysfunction in T2D, its role in a-cell
biology remains unclear. X-box binding protein 1 (XBP1) is a tran-
scription factor that plays a crucial role in the unfolded protein
response (UPR), and its deﬁciency in b-cells has been reported to
impair insulin secretion, leading to glucose intolerance. To eval-
uate the role of XBP1 in a-cells, we created complementary in
vivo (a-cell–speciﬁc XBP1 knockout [aXBPKO] mice) and in
vitro (stable XBP1 knockdown a-cell line [aXBPKD]) models.
The aXBPKO mice exhibited glucose intolerance, mild insulin
resistance, and an inability to suppress glucagon secretion after
glucose stimulation. aXBPKD cells exhibited activation of inositol-
requiring enzyme 1, an upstream activator of XBP1, leading to
phosphorylation of Jun NH2-terminal kinase. Interestingly, insulin
treatment of aXBPKD cells reduced tyrosine phosphorylation
of insulin receptor substrate 1 (IRS1) (pY
896) and phosphoryla-
tion of Akt while enhancing serine phosphorylation (pS
307)o f
IRS1. Consequently, the aXBPKD cells exhibited blunted sup-
pression of glucagon secretion after insulin treatment in the
presence of high glucose. Together, these data indicate that
XBP1 deﬁciency in pancreatic a-cells induces altered insulin
signaling and dysfunctional glucagon secretion. Diabetes
62:2439–2449, 2013
I
n addition to the defects in b-cell secretory function
and reduced b-cell mass, patients with type 2 diabetes
(T2D) frequently manifest hyperglucagonemia that
contributes to uncontrolled hyperglycemia (1–3).
Although it is generally accepted that a-cell dysfunction
is a feature of overt T2D, the mechanism(s) that con-
tribute to the hypersecretion by a-cells is not fully un-
derstood. In addition to glucose (4), we and others have
reported that insulin signaling in a-cells plays a critical
role in the regulation of glucagon secretion and that
impaired insulin signaling in a-cells leads to a diabetic
phenotype due to enhanced glucagon secretion (5,6).
Further, the a-cell has been suggested to be regulated by
other intraislet paracrine factors, such as somatostatin (7),
g-aminobutyric acid (GABA) (8), and zinc ions (Zn
2+) (9),
in addition to insulin.
A notable feature in patients with T2D is a gradual loss
of b-cell mass while their a-cell mass is maintained rela-
tively intact (10). Although hyperglycemia, elevated free
fatty acids (11), oxidative stress, and endoplasmic re-
ticulum (ER) stress (12,13) have all been proposed to
contribute to the reduced b-cell mass, the mechanisms
that underlie the relative refractoriness of a-cells that are
also exposed to these factors are not fully explored. The
development of ER stress is typically followed by an un-
folded protein response (UPR) that is mediated by three
transmembrane stress sensor proteins: PKR-like ER kinase
(PERK), inositol-requiring enzyme 1 (IRE1), and activating
transcription factor 6 (ATF6) (14–16). IRE1 cleaves the
unspliced X-box binding protein 1 (XBP1u), a member of
the cAMP-responsive element–binding protein/ATF family
of transcription factors, into the highly active spliced form
of XBP1 (XBP1s) (17–19). XBP1s promote ER biogenesis
and activate the expression of ER chaperone genes that
are required for the folding and trafﬁcking of secretory
proteins (20–22). Consistent with its critical role in facili-
tating protein secretion, XBP1 deﬁciency impairs the de-
velopment and function of professional secretory cells
such as plasma B cells (23) and pancreatic acinar cells
(24). Furthermore, a recent study reported that b-cell–
speciﬁcX B P 1 - d e ﬁcient mice (25) exhibit activation of IRE1
and b-cell dysfunction.
In the current study, we interrogated the role of XBP1 in
a-cells by creating complementary in vivo (a-cell–speciﬁc
XBP1 knockout mouse) and in vitro (stable XBP1 knock-
down or overexpression a-cell lines) models. We observed
that XBP1 deﬁciency in a-cells increased ER stress with-
out signiﬁcantly impacting a-cell survival. However, XBP1-
deﬁcient a-cells exhibited alterations in the regulation of
glucagon secretion in response to insulin due to defective
signaling as a consequence of Jun NH2-terminal kinase
(JNK) activation.
RESEARCH DESIGN AND METHODS
Mouse breeding and physiological experiments. We used male mice for all
experiments. Mice were housed in pathogen-free facilities and maintained on
a 12-h light/dark cycle at the Foster Biomedical Research Laboratory of
Brandeis University in Waltham, Massachusetts. All protocols were approved
by the Brandeis University Institutional Animal Care and Use Committee and
were in accordance with National Institutes of Health (NIH) guidelines. Blood
glucose was monitored with a Glucometer (Elite, Bayer), plasma insulin by
ELISA (Crystal Chem, Downers Grove, IL), plasma glucagon by radio-
immunoprecipitation assay(RIA;Linco,St.Charles,MO),andplasmaglucagon-
like peptide 1 (GLP-1) by ELISA (Linco). Glucose and insulin tolerance tests
were performed as described previously (26). For the pyruvate challenge test,
blood glucose was monitored at 15, 30, 60, and 120 min after an intraperitoneal
pyruvate injection (2 g/kg body weight).
Islet isolation and islet secretion assay. Islets were isolated from 6-month-
old mice, as described previously (26). After 24-h culture in 7 mmol/L glucose,
islets were used in secretion assays, as reported earlier (27). Islets were
preincubated at 37°C for 30 min in Krebs-Ringer buffer (KRB) supplemented
with 5.5 mmol/L glucose, transferred to 1.5-mL tubes (15 islets per sample),
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ORIGINAL ARTICLEand incubated in 500 mL KRB with 2.2 or 16.7 mmol/L glucose for 1 h at 37°C.
At the end of the incubation period, aliquots from each sample were stored at
220°C for glucagon and insulin assays. Islet DNA, glucagon, and insulin were
extracted from aliquots of islets, as reported earlier (27). Glucagon and insulin
were measured by RIA or ELISA, as described above.
Histological analysis and electron microscopy. Mice were anesthetized,
and the pancreas was rapidly dissected and processed, as described previously
(26), and immunostained for insulin (Abcam), glucagon (Sigma-Aldrich), and
somatostatin (Abcam). Photomicrographs were obtained with a charge-coupled
device camera, and the b-cell, a-cell, d-cell, and total pancreatic area were
estimated using ImageJ software. For transmission electron microscopy,
islets were processed by the Joslin Advanced Microscopy Core (DRC) Facility,
as reported previously (27).
Cell culture. Glucagon-secreting aTC6 cells were cultured as reported pre-
viously (6), and experiments were performed using 80–90% conﬂuent cells.
Lentiviral knockdown of XBP1, overexpression, and inducible system of
mouse spliced XBP1. Lentiviral vector plasmid for murine XBP1 short hairpin
RNA (shRNA) and control nonsilencing (NS) shRNA were purchased from
Open Biosystems. Mouse complete spliced XBP1 open reading frame was
ampliﬁed from aTC6 cDNA, after thapsigargin treatment, using PCR and
cloned into pCDH-CMV-MCS-EF1-Puro lentiviral vector (System Biosciences)
for overexpression, and SparQ dual promoter lentiviral vector (System Bio-
sciences) for inducible mouse spliced XBP1. We used SparQTM Cumate
Switch Inducible Expression System (System Biosciences) for induction of
spliced XBP1. Lentivirus particles were generated by following the manu-
facturer’s recommendation (Open Biosystems). aTC6 cells were plated 24 h
before viral infection and then incubated with lentivirus for 24 h. For gener-
ating stable cell lines, we began selection with 4 mg/mL of puromycin 48 h
after infection and maintained selection for ;14 days before experiments. We
generated three separate stable cell lines in each group.
SDS-PAGE and Western blotting. Cells were lysed in RIPA buffer, as
reported earlier, and total protein concentration was determined using
a bicinchoninic acid assay (Pierce) (27). Samples were resuspended in re-
ducing SDS-PAGE sample buffer, boiled, and resolved by SDS-PAGE. Proteins
were subsequently transferred onto polyvinylidene diﬂuoride membranes,
blocked in blocking buffer (Thermo Scientiﬁc), and incubated with primary
antibodies overnight at 4°C. XBP1, ATF6, TATA binding protein (TBP), b-actin,
C/EBP homologous protein (CHOP), and IR antibodies were from Santa
Cruz. Binding immunoglobulin protein (BiP), IRE1a,p P E R K ,p J N K ,J N K ,
p-insulin receptor substrate 1 (IRS1) (pS307), pAkt (pT308), pAkt (pS473), total
Akt, forkhead box O1 (FoxO1), and cleaved caspase 3 antibodies were from
Cell Signaling. pIRE1a antibody is from Novus Biologicals. PERK antibody
was from Rockland. pIR (pY972) and pIRS1 (pY896) antibodies are from
Invitrogen. IRS1 antibody was from Millipore. Relative protein amounts were
estimated by ImageJ software.
Cell secretionassays.Cells were preincubated for 30 min at 37°C in KRB with
25 mmol/L glucose. Subsequently, the cells were treated with 1,000 mL KRB
containing 0.5, 5.5, or 25 mmol/L glucose in a 12-well plate for 1 h. At the end
of the incubation, aliquots from each sample were used for measurement of
glucagon by RIA. Then cells were lysed for DNA extraction.
Measurements of cytoplasmic Ca
2+ concentrations. Cells on coverslips
were incubated for 40 min with 2 mmol/L Fura-2 acetoxymethyl ester at 37°C
and washed by KRB with 0.5 mmol/L glucose. Experiments were performed as
described earlier (28).
Real-time PCR. RNA was extracted from cells using RNeasy Mini Kit (QIAGEN),
and 1 mg RNA was used for a reverse transcription step using the high-capacity
cDNA Archive Kit (AppliedBiosystems). cDNA was analyzed and ampliﬁed using
the ABI 7900HT system (Applied Biosystems). TBP was used as an internal
control. Primers for glucagon: 59-TGAATTTGAGAGGCATGCTG-39 (forward)
and 59-TGGTGCTCATCTCGTCAGAG-39 (reverse) and for TBP: 59-ACCCTTCAC
CAATGACTCCTATG-39 (forward) and 59-ATGATGACTGCAGCAAATCGC-39
(reverse).
Statistical analysis. All data are expressed as means 6 SE and were analyzed
with an unpaired two-tailed Student t test or ANOVA and post hoc tests as
appropriate. Differences were considered signiﬁcant at P , 0.05.
RESULTS
a-Cell speciﬁc deletion of XBP1 causes glucose intoler-
ance and insulin resistance due to dysregulated gluca-
gon secretion. a-Cell–speciﬁc XBP1 knockout (aXBPKO)
mice were created by crossing mice carrying the Xbp1
ﬂox
allele (25,29) with mice expressing Cre recombinase driven
by the glucagon promoter (6,30). The efﬁciency of re-
combination by Glu-Cre was consistent with our previous
report (6), with ;80% of a-cells expressing b-gal (Fig. 1A).
aXBPKO mice were born normally and did not exhibit ab-
normalities in the postnatal period. Body weight, nonfasting
blood glucose, insulin, and glucagon levels did not show
signiﬁcant differences between groups until age 6 months
(Fig. 1B–E), when aXBPKO mice exhibited glucose in-
tolerance (Fig. 1F) and insulin resistance (Fig. 1G). An in-
traperitoneal injection of glucose failed to suppress glucagon
secretion in aXBPKO mice compared with a signiﬁcant
suppression in controls (Fig. 1H). Hepatic glucose pro-
duction after pyruvate injection was also higher in aXBPKO
mice compared with controls (Fig. 1I). Insulin and plasma
GLP-1 levels were not signiﬁcantly different between groups
(Fig. 1J and K).
To investigate the potential defects in secretory func-
tion, independent of systemic signals, we examined hor-
mone secretion from freshly isolated islets. As expected,
exposure of control islets to high glucose (16.7 mmol/L)
suppressed glucagon release compared with low glucose
(2.2 mmol/L), whereas glucagon secretion from aXBPKO
islets was unaffected by high glucose levels (Fig. 1L).
However, both groups exhibited a similar insulin secretory
response to high glucose stimulation (Fig. 1M), and the
glucagon and insulin content of isolated islets were not
signiﬁcantly different (Fig. 1N and O). Taken together,
these data suggest that XBP1 deﬁciency in a-cells leads to
dysregulation of glucagon secretion and altered glucose
homeostasis.
XBP1 deﬁciency in pancreatic a-cells promotes ER
stress without altering islet architecture. Histo-
morphometric analyses of pancreatic sections in 6-month-
old aXBPKO mice showed normal islet architecture (Fig.
2A and B), and no signiﬁcant differences were evident in
the relative areas of insulin, glucagon, or somatostatin-
positive cells between groups (Fig. 2C–E). Evaluation of
apoptosis by TUNEL staining and BrdU incorporation into
a-cells revealed no differences between groups (data not
shown).
To examine whether absence of XBP1 promotes ER
stress, we performed ultrastructural analyses of pancreas
sections using electron microscopy. a-Cells could be dis-
tinguished from b- and d-cells by their distinct secretory
granules (31). In the aXBPKO mouse, the ER was severely
dilated in ;70% of a-cells compared with normal archi-
tecture in controls (Fig. 2F and G). These data indicate
that XBP1 deﬁciency promotes ER stress in a-cells.
XBP1 deﬁciency leads to phosphorylation of IRE1a
and activation of JNK. To begin to investigate the
mechanisms underlying the phenotype, we generated
three independent stable aTC6 cell lines, each with a XBP1
knockdown (aXBPKD) or overexpressing mouse spliced
XBP1 (mXBP1s; aXBPOE). Stable expression of shRNA of
XBP1 or mXBP1s was achieved using a lentiviral vector to
transduce aTC6 cells. Nonsilencing shRNA and empty
vector were used as controls for knockdown and over-
expression cells, respectively. The effectiveness of knock-
down or overexpression of the target protein was conﬁrmed
by Western blotting (Fig. 3A and D). In aXBPKD cells, the
expression of XBP1s was reduced by ;85% after thapsigargin
treatment compared with controls, and the expression of
XBP1s in aXBPOE cells was ;10-fold higher than control
cells in the basal state.
Next, we examined the proteins associated with the
UPR by Western blotting. As expected, the expression of
BiP, a downstream target of XBP1s, was decreased in
aXBPKD cells (Fig. 3B and C). However, pIRE1a, a protein
upstream of XBP1, was increased in aXBPKD cells, even
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2440 DIABETES, VOL. 62, JULY 2013 diabetes.diabetesjournals.orgFIG. 1. a-Cell speciﬁc deletion of XBP1 promotes glucose intolerance, insulin resistance, and hyperglucagonemia. A: Immunoﬂuorescence staining
for glucagon (red), b-gal (green), and DAPI (blue) of pancreatic sections from glucagon-Cre/ROSA26-LacZ mice. Scale bar, 100 mm. B: Body
weights (n =6 –10 in each group). Nonfasting blood glucose (C), nonfasting insulin (D), and nonfasting glucagon (E) in 6-month-old male mice (n =
6 in each group). F: Intraperitoneal glucose tolerance test (ipGTT; glucose 2 g/kg body weight [BW]) in 6-month-old male mice (n = 6 in each
group). G: Whole-body insulin sensitivity by insulin tolerance test (ITT; insulin 0.75 units/kg BW) in 6-month-old male mice (n =7 –11 in
each group). H: Plasma glucagon levels before and after intraperitoneal glucose injection (glucose 2 g/kg BW) in 6-month-old male mice (n =7i n
each group). I: Intraperitoneal pyruvate challenge (pyruvate 2 g/kg BW) in 6-month-old male mice (n =8 –10 in each group). J: Plasma insulin levels
before and after intraperitoneal glucose injection (glucose 2 g/kg BW) in 6-month-old male mice (n = 7 in each group). K: GLP-1 levels before and
after oral glucose gavage (at glucose doses 1 g/kg BW; n =3 –4 in each group). Glucagon (L) and insulin secretion (M) from islets were expressed
per microgram of total DNA (n =3 –4 in each group). Total glucagon (N), and total insulin (O) content of islets expressed per microgram of total
DNA (n =3 –4 in each group). Data are expressed as means 6 SEM. *P < 0.05, **P < 0.01, ***P < 0.001; n.s., not signiﬁcant; control vs. aXBPKO.
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ﬁrm the feedback regulation of IRE1a by XBP1 in a-cells,
a feature that has been reported in other cell types, in-
cluding b-cells (25). Examination of other UPR markers
revealed increased active ATF6 and reduced pPERK in
aXBPKD cells compared with control cells (Fig. 3A–C). To
explore the effects of ER stress on activation of JNK (32),
we examined the expression of pJNK in the aXBPKD cells.
As expected, pJNK was upregulated in aXBPKD cells
compared with controls (Fig. 3B and C). The expression
levels of BiP, pIRE1a, and pJNK in aXBPOE cells were
virtually opposite to that observed in aXBPKD cells.
FIG. 2. a-Cell speciﬁc deletion of XBP1 causes ER stress but not cell death. Immunoﬂuorescence staining (shown by grayscale) for insulin, glu-
cagon, and somatostatin of pancreatic sections from control mice (A) and aXBPKO mice (B) at age 6 months (scale bar, 200 mm). Areas positive
for insulin (C), glucagon (D), and somatostatin (E) are shown relative to total pancreas at age 6 months (n = 3 in each group) for control and
aXBPKO mice. Data are expressed as means 6 SEM. Ultrastructural analysis of pancreatic a-cells using electron microscopy was performed on
islets from control (F)a n daXBPKO (G) mice at age 6 months (scale bar, 2 mm). The magniﬁcation for the enlarged inset is 3 43,860 (F)a n d3
32,520 (G).
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was similar in aXBPKD and aXBPOE cells compared with
their respective controls (Fig. 3D–F). Taken together, these
data suggest feedback mechanisms between XBP1 and
IRE1a and that XBP1 deﬁciency activates IRE1a and
phosphorylation of JNK. The alterations in ATF6 and PERK
warrant further investigation.
XBP1 deﬁciency impairs insulin signaling and insulin
suppression of glucagon secretion. We next examined
the effects of activation of JNK on phosphorylation of
IRS1. As expected, IRS1 serine phosphorylation, which has
been shown to have a negative effect on IRS1 signaling in
some studies (33), was signiﬁcantly increased in the basal
state in aXBPKD cells compared with controls (Fig. 4A
and B). In contrast, IRS1 tyrosine phosphorylation was
signiﬁcantly lower, and consequently, Akt Thr
308 and Akt
Ser
473 phosphorylation were both markedly decreased in
aXBPKD cells after insulin stimulation (Fig. 4A and B). In
FIG. 3. Activated IRE1a due to XBP1 deﬁciency leads to activation of JNK. Western blotting for spliced XBP1, active ATF6, and TBP (loading
control) in control or aXBPKD cell lines (A) and in control or aXBPOE cell lines (D) before and after thapsigargin (Tg) treatment for 4 h (100
nmol/L) using nuclear fractions. Western blotting for BiP, pIRE1a, IRE1a, pPERK, PERK, pJNK, JNK, and b-actin (loading control) in control or
aXBPKD cell lines (B) and in control or aXBPOE cell lines (E) before and after thapsigargin (Tg) treatment for 4 h (100 nmol/L). Quantiﬁcation is
shown for active ATF6/TBP, BiP/actin, pIRE1/IRE1, pPERK/PERK, and pJNK/JNK in control or aXBPKD cell lines (C) and in control or aXBPOE
cell lines (F). Data are expressed as means 6 SEM. *P < 0.05, **P < 0.01, ***P < 0.001. ND, not detected.
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diabetes.diabetesjournals.org DIABETES, VOL. 62, JULY 2013 2443FIG. 4. XBP1 deﬁciency impairs insulin signaling. Western blotting for insulin receptor (IR) tyrosine
972 (Y) phosphorylation (pIR), IR, IRS1 ty-
rosine
896 (Y) phosphorylation, IRS1 Ser
307 (Ser) phosphorylation, total IRS1, Akt Thr
308 phosphorylation, Akt Ser
473 phosphorylation, total Akt,
and b-actin (loading control) in control or aXBPKD cell lines (A) and in control or aXBPOE cell lines (D) before and after insulin (ins) treatment
for 10 min (100 nmol/L). Quantiﬁcation of pIRS1(Y)/IRS1, pIRS1(Ser)/IRS1, pAkt(T308)/Akt, and pAkt(S473)/Akt in control or aXBPKD cell lines
(B) and in control or aXBPOE cell lines (E). Data are expressed as means 6 SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Glucagon secretion from
control or aXBPKD cell lines (C) and control or aXBPOE cell lines (F) was assessed by static incubation for 60 min under various glucose
concentrations, without or with 100 nmol/L insulin (Ins), and expressed per microgram of total DNA (n =3 –6 in each group). Data are expressed as
means 6 SEM. *P < 0.05, **P < 0.01; n.s., not signiﬁcant.
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serine phosphorylation after insulin stimulation, although
IRS1 tyrosine phosphorylation, Akt Thr
308 phosphorylation,
and Akt Ser
473 phosphorylation were not signiﬁcantly
different compared with control cells (Fig. 4D and E).
On the basis of our previous report that impaired insulin
signaling in a-cells leads to enhanced glucagon secretion
(6), we hypothesized that aXBPKD cells would exhibit an
inability to suppress glucagon secretion by insulin. Ex-
amination of control cells revealed that glucagon secretion
was maximally suppressed at 5.5 mmol/L glucose com-
pared with 0.5 or 25 mmol/L glucose (Fig. 4C and F). These
results are consistent with previous reports showing
maximal suppression of glucagon secretion at ;7 mmol/L
glucose concentration but paradoxically increased at
higher glucose (.10 mmol/L) (34). In addition, insulin in
the concentration range between 1 pmol/L and 1 mmol/L
has been reported to suppress glucagon secretion from
aTC6 cells in the presence of high glucose (25 mmol/L)
(35). However, the failure of 100 nmol/L insulin to sup-
press glucagon secretion in the presence of high glu-
cose (25 mmol/L) suggests impaired insulin signaling in
aXBPKD cells (Fig. 4C). Glucagon secretion was not sig-
niﬁcantly different between control and aXBPOE cells
(Fig. 4F).
Consistent with the data in aXBPKO mouse a-cells, our
observation in aXBPKD cells suggests that XBP1 de-
ﬁciency impairs insulin signaling and induces the inability
of insulin to suppress glucagon secretion.
Alterations in cytoplasmic Ca
2+ in XBP1-deﬁcient
a-cells. Next, we measured cytoplasmic Ca
2+ concen-
trations ([Ca
2+]) to assess the mechanism of dysregulation
of glucagon secretion in aXBPKD cells. Consistent with
previous reports (4,34), cytoplasmic [Ca
2+] oscillations in
control cells were dampened by application of high glu-
cose and insulin (Fig. 5A, C, and F). A similar trend was
evident in aXBPKD cells, although the response was
blunted compared with control cells (Fig. 5A, B, and F).
However, the average [Ca
2+] level in aXBPKD cells when
incubated in 0.5 or 25 mmol/L glucose or in 25 mmol/L
glucose with 100 nmol/L insulin, was not signiﬁcantly dif-
ferent from control cells (Fig. 5A, B, and E). On the other
hand, the basal [Ca
2+] was signiﬁcantly higher in aXBPOE
cells compared with controls, although the [Ca
2+] oscil-
lations were similar in the two groups (Fig. 5C–F). These
data suggest that alterations in [Ca
2+] are unlikely to un-
derlie the dysregulation of glucagon secretion in XBP1
deﬁcient a-cells. Further studies are warranted to carefully
dissect the alterations in [Ca
2+] when the expression levels
of XBP1 are manipulated.
Chronic XBP1 deﬁciency in a-cell line leads to
decreased glucagon gene expression. Because our
experiments in aXBPKD cells suggested a role for XBP1 in
the regulation of glucagon secretion, we next examined
potential effects at the transcriptional level. Consistent
with earlier reports (36,37), glucagon gene expression in
control cells was signiﬁcantly suppressed by insulin at
a glucose concentration of 10 mmol/L but not at 2.8 mmol/L
(Fig. 6A and B). In contrast, glucagon gene expression in
aXBPKD cells was not suppressed by insulin, although
basal glucagon gene expression was lower (Fig. 6A). On
the other hand, interestingly, the ability of exogenous in-
sulin to inhibit glucagon gene expression was obvious in
aXBPOE cells (Fig. 6B).
We next examined the expression of nuclear FoxO1 be-
cause it has been reported to directly bind the preproglucagon
gene promoter and regulate glucagon gene expression
(37). In aXBPKD cells, nuclear FoxO1 was already de-
creased compared with control cells in the basal state,
and insulin stimulation did not promote further exclusion
of FoxO1 from the nucleus (Fig. 6C and E). In contrast,
stimulation of aXBPOE cells with exogenous insulin had
as i g n i ﬁcant effect on FoxO1 exclusion from the nucleus
(Fig. 6D and E). Together, these data suggest that XBP1
regulates glucagon gene expression via the FoxO1 pathway
in a-cells.
Acute induction of spliced XBP1 promotes apoptosis,
whereas XBP1 deﬁciency blocks apoptosis signaling.
Histological analyses of pancreas sections from aXBPKO
mice showed a normal complement of islet cells, in-
dicating that absence of XBP1 does not enhance a-cell
death in the basal state in vivo (Fig. 2). Therefore, we next
sought to study the effects of XBP1 on cell growth and
apoptosis in our in vitro models. First, examination of
growth in aXBPKD and aXBPOE cells did not show sig-
niﬁcant differences between groups when compared with
their respective controls (Fig. 7A and B). CHOP, a proa-
poptotic protein induced by ER stress, and active caspase
3 were signiﬁcantly lower in aXBPKD cells in the basal
state and after thapsigargin treatment (Fig. 7C and D).
Surprisingly, aXBPOE cells also exhibited a decrease in
CHOP expression after thapsigargin treatment, whereas
expression of active caspase 3 was not signiﬁcantly altered
(Fig. 7E and F). One potential explanation for this con-
ﬂicting result is that aXBPOE is a stable cell line that
expresses high levels of XBP1s. This prompted us to
design an experiment to examine the effects of “acute”
overexpression of XBP1s by using cumate to induce
XBP1s (38). After conﬁrmation of induction of XBP1s by
Western blotting (Fig. 8A), and consistent with an in-
creased expression of XBP1s, the downstream target BiP
was upregulated in the basal state (Fig. 8B). Interestingly,
CHOP and active caspase 3 expression were both signiﬁ-
cantly increased after acute induction of XBP1s (Fig. 8B).
Although there was no difference in the expression of
pIRE1a, phosphorylation of JNK was signiﬁcantly upre-
gulated by acute induction of XBP1s (Fig. 8B). The acti-
vation of JNK is possibly related to apoptosis induced by
acute induction of XBP1s, because JNK is generally acti-
vated by various cellular stress pathways (39). The ex-
pression of active ATF6 and pPERK after induction of
XBP1s showed a trend that was similar to that observed in
aXBPOE cells (Fig. 8A and B). These results from com-
plementary models suggest that acute induction of XBP1s
promotes, whereas a knockdown of XBP1 attenuates, ap-
optosis in a-cells.
DISCUSSION
To directly examine the role of XBP1, a transcription
factor that plays a crucial role in the unfolded protein re-
sponse in pancreatic a-cells, we created and phenotyped
mice with a conditional knockout of XBP1 (aXBPKO
mice). Here, we report that aXBPKO mice exhibit dysre-
gulation of glucagon secretion and impaired glucose tol-
erance that is secondary to activation of the IRE1a-JNK
pathway and consequent inhibition of IRS1 signaling leading
to altered insulin action.
Although impaired glucose utilization due to insulin re-
sistance contributes to the hyperglycemia in patients with
T2D, an increase in hepatic glucose production due to al-
tered gluconeogenesis also contributes (40). In normal
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glucose ingestion, whereas in subjects with T2D, the levels
remain high (41), and some patients also exhibit a para-
doxical increase in glucagon levels (42). Thus, an inability
to suppress glucose production from the liver due to in-
creased glucagon levels is associated with postprandial
hyperglycemia in T2D patients. One possible mechanism
underlying the hyperglucagonemia in T2D is impaired in-
sulin signaling in a-cells that prevents the appropriate
suppression of glucagon secretion. Indeed, mice with func-
tional disruption of insulin receptors in a-cells (aIRKO) ex-
hibit enhanced glucagon secretion and a diabetic phenotype
(6). The similar phenotypes of the aXBPKO and aIRKO
models support the notion that ER stress in a-cells is
linked to altered insulin signaling and contributes to the
postprandial hyperglucagonemia in T2D.
Among secretory cells, the b-cell is highly susceptible to
ER stress (12,13), which may partly contribute to a signif-
icant reduction in b-cell mass in T2D, whereas a-cell mass
is relatively normal (10), despite being exposed to high
glucose and/or high free fatty acid levels. Our observation
that absence of XBP1 did not affect a-cell mass in the
aXBPKO mice or cell growth in the aXBPKD cells indi-
cates that a-cells are relatively resistant to ER stress. One
FIG. 5. Effects of altered XBP1 expression on [Ca
2+]i naTC6 cells. The glucose (G) concentration was increased from 0.5 to 25 mmol/L, and 100
nmol/L human insulin was present as indicated. Representative traces are shown of single cells from control for KD (A), aXBPKD cell (B), control
for OE (C), and aXBPOE cells (D). E: Basal [Ca
2+] is shown for each group (n =9 –15 in each group). Data are expressed as means 6 SEM. ***P <
0.0001. F: Quantiﬁcation of frequency of spikes from each group (n =8 –16). Data are expressed as means 6 SEM. *P < 0.05, **P < 0.01, ***P <
0.001; n.s., not signiﬁcant.
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are unaffected by lack of XBP1 is a relatively lower de-
mand for glucagon secretion compared with insulin.
Nevertheless, the selective regulatory effect of XBP1 on
hormone secretion but not on cell growth in the a-cell
requires further investigation. It is also worth noting that
XBP1 plays diverse roles in other cell types. For example,
XBP1-deﬁcient lymphoid chimeric mice are completely
deﬁcient in normal plasma B cells, although the number
of activated B lymphocytes are normal (23), suggesting
that XBP1 is required for the terminal differentiation of B
lymphocytes to plasma cells. On the other hand, the de-
letion of XBP1 in pancreatic acinar cells (24) and in-
testinal Paneth cells (43) promoted death by apoptosis
during development. In hepatocytes and salivary gland
acinar cells, XBP1 deﬁciency led to a modest reduction of
secretory protein (24,29) but did not result in cell death
or any other overt pathology in these cells, suggesting
that XBP1 is essential in a small subset of highly secretory
cells.
Hepatocytes and adipocytes have both been reported to
be susceptible to ER stress in response to obesity and
exhibit inhibition of insulin signaling (44), whereas neu-
ronal cells in the brain manifest altered leptin signaling
(45). Further, XBP1 deﬁciency in the liver or adipose tis-
sue induces the activation of IRE1a and of JNK, with
a consequent inhibition of insulin signaling (44), a ﬁnding
that is also evident in the aXBPKD cells. Taken together,
our ﬁndings suggest that downregulation of PI3K-Akt sig-
naling is associated with unsuppressed glucagon secretion
in XBP1-deﬁcient a-cells. However, the recent report that
IRS1 serine phosphorylation is beneﬁcial to insulin sig-
naling (46) suggests the effects mediated by the IRS1/JNK
pathway are dependent on context and/or cell type. The
reduction in nuclear translocation of XBP1s in the livers of
obese mice (47) suggests that obesity promotes XBP1s
deﬁciency in hepatocytes. Whether obesity similarly affects
other tissues, including a-cells, with consequent defects in
dysregulation of glucagon secretion and hyperglucagonemia
is not understood and requires investigation.
The lack of a signiﬁcant alteration in [Ca
2+]i naXBPKD
cells, despite an increase in glucagon secretion, suggests
cAMP is a dominant second messenger in the regulation of
glucagon secretion in a-cells (48). Consistent with this
possibility, other studies have reported that glucagon se-
cretion at high glucose concentrations does not require el-
evation of [Ca
2+]( 3 4 ) .
The complementary alteration in glucagon gene ex-
pression in aXBPKD and aXBPOE cells indicates that
XBP1 regulates glucagon gene expression via FoxO1 and
is consistent with previous reports in hepatocytes that
XBP1 directly interacts with FoxO1 (49). However, the
signiﬁcantly lower basal glucagon gene expression in
aXBPKD cells, despite a relatively normal glucagon se-
cretion, suggests the regulation of glucagon translation is
independent of mechanisms that modulate gene expres-
sion. It is possible that the mammalian target of rapamycin
complex 1 pathway, a downstream target of Akt that
FIG. 6. Effect of XBP1 knockdown or overexpression on glucagon gene
expression. Real-time PCR of glucagon gene expression of control or
aXBPKD cells (A) and control or aXBPOE cells (B) incubated at 2.8
and 10 mmol/L glucose concentration with/without 100 nmol/L insulin
(Ins) for 6 h. Value were normalized by the level of TBP, and fold-
changes were calculated relative to control without insulin (n =3i n
each group). Data are expressed as means 6 SEM. *P < 0.05, **P <
0.01, ***P < 0.001. Western blotting for FoxO1 and TBP (loading con-
trol) in control or aXBPKD cell lines (C) and in control or aXBPOE cell
lines (D) before and after insulin (ins) treatment for 3 h (100 nmol/L)
using nuclear fraction. E: Quantiﬁcation of FoxO1/TBP in control or
aXBPKD cell lines and in control or aXBPOE cell lines before and after
insulin treatment. Data are expressed as means 6 SEM. **P < 0.01,
***P < 0.001.
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mechanism.
In summary, we report that XBP1 interacts with proteins
in the insulin-signaling pathway to regulate glucagon se-
cretion in a-cells. We propose that ER stress in a-cells
contributes to hyperglucagomemia and altered glucose
homeostasis and that ER chaperones could be used in
therapeutic approaches to modify a-cell function in T2D.
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